Pleural infection: Changing bacteriology and its implications

Respirology

Volumn 16, Issue 4, 2011, Pages 598-603

  Lisboa, Thiago ^a,e   Waterer, Grant W ^b,c   Lee, Y C Gary ^b,d  

^a HOSPITAL SANTA RITA   (Brazil)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^c ROYAL PERTH HOSPITAL   (Australia)

^d SIR CHARLES GAIRDNER HOSPITAL   (Australia)

^e HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

Author keywords

aetiology; empyema; infection; pleural; pneumonia

Indexed keywords

PNEUMOCOCCUS VACCINE;

ARTICLE; BACTERIAL STRAIN; BACTERIOLOGY; HOSPITAL INFECTION; HUMAN; INFECTION CONTROL; INFECTION PREVENTION; PLEURA EMPYEMA; PRIORITY JOURNAL; SEROTYPE; STREPTOCOCCUS PNEUMONIAE;

BACTERIAL INFECTIONS; COMMUNITY-ACQUIRED INFECTIONS; CROSS INFECTION; EMPYEMA, PLEURAL; HUMANS; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; SEROTYPING;

EID: 79955384752     PISSN: 13237799     EISSN: 14401843     Source Type: Journal    
DOI: 10.1111/j.1440-1843.2011.01964.x     Document Type: Article

References (64)

1. Tassi GF, Marchetti GP,. Pleural disease: historic perspective. In:, Light RW, Lee YCG, (eds) Textbook of Pleural Diseases, 2nd edn. Arnold Press, London, 2008; 1-9.
2. Brims FJ, Lansley SM, Waterer GW, et al,. Empyema Thoracic - new insights into an old disease. Eur. Respir. Rev. 2010; 19: 220-8.
3. Colice GL, Curtis A, Deslauriers J, et al,. Medical and surgical treatment of parapneumonic effusions: an evidence-based guideline. Chest 2000; 118 (4): 1158-71.
4. Strachan R, Jaffé A,. Australian Research Network in Empyema. A.ssessment of the burden of paediatric empyema in Australia. J. Paediatr. Child Health 2009; 45: 431-6.
5. Wu PS, Huang LM, Chang IS, et al,. The epidemiology of hospitalized children with pneumococcal/lobar pneumonia and empyema from 1997 to 2004 in Taiwan. Eur. J. Pediatr. 2010 (in press).
6. Byington CL, Hulten KG, Ampofo K, et al,. Molecular epidemiology of pediatric pneumococcal empyema from 2001 to 2007 in Utah. J. Clin. Microbiol. 2010; 48: 520-5.
7. Li ST, Tancredi DJ,. Empyema hospitalizations increased in US children despite pneumococcal conjugate vaccine. Pediatrics 2010; 125: 26-33.
8. Hendrickson DJ, Blumberg DA, Joad JP, et al,. Five-fold increase in pediatric parapneumonic empyema since introduction of pneumococcal conjugate vaccine. Pediatr. Infect. Dis. J. 2008; 27: 1030-2.
9. Munoz-Almagro C, Jordan I, Gene A, et al,. Emergence of invasive pneumococcal disease caused by nonvaccine serotypes in the era of 7-valent conjugate vaccine. Clin. Infect. Dis. 2008; 46: 174-82. (Pubitemid 351269154)
10. Goldbart AD, Leibovitz E, Porat N, et al,. Complicated community acquired pneumonia in children prior to the introduction of the pneumococcal conjugated vaccine. Scand. J. Infect. Dis. 2009; 41: 182-7.
11. Finley C, Clifton J, Fitzgerald JM, et al,. Empyema: an increasing concern in Canada. Can. Respir. J. 2008; 15: 85-9. (Pubitemid 351676396)
12. Grijalva CG, Nuorti JP, Zhu Y, et al,. Increasing incidence of empyema complicating childhood community-acquired pneumonia in the United States. Clin. Infect. Dis. 2010; 50: 805-13.
13. Roxburgh CS, Youngson GG, Townend JA, et al,. Trends in pneumonia and empyema in Scottish children in the past 25 years. Arch. Dis. Child 2007; 93: 316-8.
14. Farjah F, Symons RG, Krishnadasan B, et al,. Management of pleural space infections: a population-based analysis. J. Thorac. Cardiovasc. Surg. 2007; 133: 346-51.
15. Maskell NA, Davies CW, Nunn AJ, et al,. U.K. Controlled trial of intrapleural streptokinase for pleural infection. N. Engl. J. Med. 2005; 352: 865-74. (Pubitemid 40300295)
16. Bender JM, Ampofo K, Sheng X, et al,. Parapneumonic empyema deaths during past century, Utah. Emerg. Infect. Dis. 2009; 15: 44-8.
17. Meyer CN, Rosenlund S, Nielsen J, et al,. Bacteriological aetiology and antimicrobial treatment of pleural empyema. Scand. J. Infect. Dis. (in press).
18. Maskell NA, Batt S, Hedley EL, et al,. The bacteriology of pleural infection by genetic and standard methods and its mortality significance. Am. J. Respir. Crit. Care Med. 2006; 174: 817-23. (Pubitemid 44511664)
19. Wong CA, Donald F, Macfarlane JT,. Streptococcus milleri pulmonary disease: a review and clinical description of 25 patients. Thorax 1995; 50: 1093-6.
20. Ahmed RA, Marrie TJ, Huang JQ,. Thoracic empyema in patients with community-acquired pneumonia. Am. J. Med. 2006; 119: 877-83. (Pubitemid 44415617)
21. Lindstrom ST, Kolbe J,. Community acquired parapneumonic thoracic empyema: predictors of outcome. Respirology 1999; 4: 173-9. (Pubitemid 29268717)
22. Mongkolrattanothai K, Aldag JC, Mankin P, et al,. Epidemiology of community-onset Staphylococcus aureus infections in pediatric patients: an experience at a Children's Hospital in central Illinois. BMC Infect. Dis. 2009; 9: 112.
23. Lin YT, Chen TL, Siu LK, et al,. Clinical and microbiological characteristics of community-acquired thoracic empyema or complicated parapneumonic effusion caused by Klebsiella pneumoniae in Taiwan. Eur. J. Clin. Microbiol. Infect. Dis. 2010; 29: 1003-10.
24. Tu CY, Hsu WH, Hsia TC, et al,. The changing pathogens of complicated parapneumonic effusions or empyemas in a medical intensive care unit. Intensive Care Med. 2006; 32: 570-6.
25. Ruolff KL,. Streptococcus. In:, Murray PR, Baron EJ, Pfaller MA, et al. (eds) Manual of Clinical Microbiology, 6th edn. American Society for Microbiology, Washington, DC, 1995; 299-307.
26. Kobashi Y, Mouri K, Yagi S, et al,. Clinical analysis of cases of empyema due to Streptococcus milleri group. Jpn. J. Infect. Dis. 2008; 61: 484-6.
27. Jerng JS, Hsueh PR, Teng LJ, et al,. Empyema thoracis and lung abscess caused by viridans streptococci. Am. J. Respir. Crit. Care Med. 1997; 156 (5): 1508-14.
28. Pratter MR, Irwin RS,. Viridans streptococcal pulmonary parenchymal infections. JAMA 1980; 243: 2515-7. (Pubitemid 10039245)
29. Sarkar TK, Murarka RS, Gilardi GL,. Primary Streptococcus viridans pneumonia. Chest 1989; 96 (4): 831-4. (Pubitemid 19256187)
30. Shinzato T, Saito A,. A mechanism of pathogenicity of 'Streptococcus milleri group' in pulmonary infection: synergy with an anaerobe. J. Med. Microbiol. 1994; 40 (2): 118-23.
31. Shinzato T, Saito A,. The Streptococcus milleri group as a cause of pulmonary infections. Clin. Infect. Dis. 1995; 21 (Suppl. 3): S238-43. (Pubitemid 26059789)
32. Buckingham SC, King MD, Miller ML,. Incidence and etiology of complicated parapneumonic effusions in children, 1996 to 2001. Pediatr. Infect. Dis. J. 2003; 22: 499-504. (Pubitemid 36782188)
33. Gonzalez BE, Hulten KG, Dishop MK, et al,. Pulmonary manifestations in children with invasive community-acquired Staphylococcus aureus infection. Clin. Infect. Dis. 2005; 41: 583-90. (Pubitemid 41170343)
34. Micek ST, Dunne M, Kollef MH,. Pleuropulmonary complications of Panton-Valentine leukocidin-positive community-acquired methicillin-resistant Staphylococcus aureus: importance of treatment with antimicrobials inhibiting exotoxin production. Chest 2005; 128: 2732-8. (Pubitemid 41507634)
35. Contreras GA, Pérez N, Murphy JR, et al,. Empyema necessitans and acute osteomyelitis associated with community-acquired methicillin-resistant Staphylococcus aureus in an infant. Biomedica 2009; 29: 506-12.
36. Chen W, Lin YC, Liang SJ, et al,. Hospital-acquired thoracic empyema in adults: a 5-year study. South. Med. J. 2009; 6: 6.
37. Blaschke AJ, Heyrend C, Byington CL, et al,. Molecular analysis improves pathogen identification and epidemiologic study of pediatric parapneumonic empyema. Pediatr. Infect. Dis. J. 2011; 30: 289-94.
38. Le Monnier A, Carbonnelle E, Zahar JR, et al,. Microbiological diagnosis of empyema in children: comparative evaluations by culture, polymerase chain reaction, and pneumococcal antigen detection in pleural fluids. Clin. Infect. Dis. 2006; 42: 1135-40.
39. Saglani S, Harris KA, Wallis C, et al,. Empyema: the use of broad range 16S rDNA PCR for pathogen detection. Arch. Dis. Child 2005; 90: 70-3. (Pubitemid 40052259)
40. Thomson A,. Pleural infection in children. Intl. Pleural. Newltr. 2006; 4: 7-8.
41. Langley JM, Kellner JD, Solomon N, et al,. Empyema associated with community-acquired pneumonia: a Pediatric Investigator's Collaborative Network on Infections in Canada (PICNIC) study. BMC Infect. Dis. 2008; 8: 129.
42. Eastham KM, Freeman R, Kearns AM, et al,. Clinical features, aetiology and outcome of empyema in children in the north east of England. Thorax 2004; 59: 522-5. (Pubitemid 38797527)
43. Barnes NP, Hull J, Thomson AH,. Medical management of parapneumonic pleural disease. Pediatr. Pulmonol. 2005; 39: 127-34. (Pubitemid 40205048)
44. Fletcher M, Leeming J, Cartwright K, et al,., Group. SWoEICAIS. Childhood empyema: limited potential impact of 7-valent pneumococcal conjugate vaccine. Pediatr. Infect. Dis. J. 2006; 25: 559-60. (Pubitemid 43863370)
45. Byington CL, Korgenski K, Daly J, et al,. Impact of the pneumococcal conjugate vaccine on pneumococcal parapneumonic empyema. Pediatr. Infect. Dis. J. 2006; 25: 250-4. (Pubitemid 43379067)
46. Darkes MJ, Plosker GL,. Pneumococcal conjugate vaccine (Prevnar; PNCRM7): a review of its use in the prevention of Streptococcus pneumoniae infection. Paediatr Drugs. 2002; 4: 609-30. (Pubitemid 34983406)
47. Lexau CA, Lynfield R, Danila R, et al,. Changing epidemiology of invasive pneumococcal disease among older adults in the era of pediatric pneumococcal conjugate vaccine. JAMA 2005; 294: 2043-51. (Pubitemid 41539937)
48. Dunais B, Bruno P, Carsenti-Dellamonica H, et al,. Trends in nasopharyngeal carriage of Streptococcus pneumoniae among children attending daycare centers in southeastern France from 1999 to 2006. Pediatr. Infect. Dis. J. 2008; 27: 1033-5.
49. Millar EV, O'Brien KL, Watt JP, et al,. Effect of community-wide conjugate pneumococcal vaccine use in infancy on nasopharyngeal carriage through 3 years of age: a cross-sectional study in a high-risk population. Clin. Infect. Dis. 2006; 43 (1): 8-15. (Pubitemid 43939070)
50. Black S, Shinefield H, Fireman B, et al,. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group. Pediatr. Infect. Dis. J. 2000; 19: 187-95. (Pubitemid 30167436)
51. Millar EV, Watt JP, Bronsdon MA, et al,. Indirect effect of 7-valent pneumococcal conjugate vaccine on pneumococcal colonization among unvaccinated household members. Clin. Infect. Dis. 2008; 47: 989-96.
52. Shafinoori S, Ginocchio CC, Greenberg AJ, et al,. Impact of pneumococcal conjugate vaccine and the severity of winter influenza-like illnesses on invasive pneumococcal infections in children and adults. Pediatr. Infect. Dis. J. 2005; 24 (1): 10-6. (Pubitemid 40353310)
53. Whitney CG, Farley MM, Hadler J, et al,. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N. Engl. J. Med. 2003; 348: 1737-46. (Pubitemid 36514704)
54. Van Ackere T, Proesmans M, Vermeulen F, et al,. Complicated parapneumonic effusion in Belgian children: increased occurrence before routine pneumococcal vaccine implementation. Eur. J. Pediatr. 2009; 168: 51-8.
55. Byington CL, Spencer LY, Johnson TA, et al,. An epidemiological investigation of a sustained high rate of pediatric parapneumonic empyema: risk factors and microbiological associations. Clin. Infect. Dis. 2002; 34: 434-40. (Pubitemid 34112262)
56. Hardie W, Bokulic R, Garcia VF, et al,. Pneumococcal pleural empyemas in children. Clin. Infect. Dis. 1996; 22: 1057-63. (Pubitemid 26260612)
57. Finland M, Barnes MW,. Changes in occurrence of capsular serotypes of Streptococcus pnuemoniae at Boston City Hospital during selected years between 1935 and 1974. J. Clin. Microbiol. 1977; 5: 154-66. (Pubitemid 8052718)
58. Byington CL, Samore M, Stoddard GJ, et al,. Temporal trends of invasive disease due to Streptococcus pneumoniae among children in the intermountain west: emergence of nonvaccine serogroups. Clin. Infect. Dis. 2005; 41: 21-9. (Pubitemid 40863739)
59. Luján M, Gallego M, Belmonte Y, et al,. Influence of pneumococcal serotype group on outcome in adults with bacteremic pneumonia. Eur. Respir. J. 2010; 36: 1073-9.
60. Kyaw MH, Lynfield R, Schaffner W, et al,. Active Bacterial Core Surveillance of the Emerging Infections Program Network. Effect of introduction of the pneumococcal conjugate vaccine on drug-resistant Streptococcus pneumoniae. N. Engl. J. Med. 2006; 354: 1455-63.
61. Farrell DJ, Klugman KP, Pichichero M,. Increased antimicrobial resistance among nonvaccine serotypes of Streptococcus pneumoniae in the pediatric population after the introduction of 7-valent pneumococcal vaccine in the United States. Pediatr. Infect. Dis. J. 2007; 26: 123-8. (Pubitemid 46183361)
62. Porat N, Arguedas A, Spratt BG, et al,. Emergence of penicillin- nonsusceptible Streptococcus pneumoniae clones expressing serotypes not present in the antipneumococcal conjugate vaccine. J. Infect. Dis. 2004; 190: 2154-61. (Pubitemid 39636363)
63. Bekri H, Cohen R, Varon E, et al,. [Streptococcus pneumoniae serotypes involved in children with pleural empyemas in France]. Arch. Pediatr. 2007; 14: 239-43. (Pubitemid 46357614)
64. Picazo J, Ruiz-Contreras J, Hernandez B, et al,. Clonal and clinical profile of Streptococcus pneumoniae serotype 19A causing pediatric invasive infections: a 2-year (2007-2009) laboratory-based surveillance in Madrid. Vaccine 2011; 29: 1770-6.